FDA releases a guidance on “Labeling for Human Prescription Drug and Biological Products – Implementing the PLR Content and Format Requirements”.  This guidance is intended to assist applicants in complying with the content and format requirements of labeling for human prescription drug and biological products under 21 CFR 201.56(d) and 201.57. FDA is issuing this guidance to provide recommendations for applicants developing labeling for new prescription drugs and revising labeling for already approved prescription drugs. This guidance also provides recommendations on developing Highlights of Prescribing Information (Highlights), formatting labeling, and procedural information.


Posted on the FDA website on 22 February 2013